Introduction
The introduction of antiretroviral therapy (ART) has been crucial in reducing HIV-related morbidity and mortality as well as improving quality of life. [1] [2] [3] Initiating ART treatment as soon as possible after HIV-infection has been demonstrated to reduce viral load, and decrease transmission. 4 Randomized trials assessing the effects of treatment initiation at higher rather than lower CD4 cell counts have tended to focus on patients initiating ART with a CD4 cell count <500 cells/mm 3 . [4] [5] [6] [7] [8] These results along with data from observational studies have provided strong evidence for the initiation of ART among patients with CD4 cell counts >350 cells/mm 3 . 6 In 2018 there were approximately 7.5 million people living with HIV in South Africa; 9 however only slightly more than half, 4.4 million (59%) were receiving ART. 10 South Africa's national ART guidelines have shifted over time towards higher initiation thresholds, [11] [12] [13] [14] and in September 2016 the country implemented the World Health Organization's (WHO) recommendation of Universal Test and Treat (UTT). 14 These expanded guidelines call for ART initiation of all known HIV-positive patients, irrespective of traditionally used clinical indicators/thresholds such as CD4 cell counts. 14, 15 Expanded guidelines are critical to getting more patients onto HIV treatment, but the increasing numbers of patients eligible for treatment could negatively impact clinics if they cannot keep up with demand. 16 For providers, an increase in patient volumes may strain health-care workers and reduce quality of services, while for patients, increased access to treatment for those with higher CD4 cell counts could lead to increased attrition from care if those newly eligible patients do not see care as a priority. As South Africa progresses towards the United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets, 17 high rates of lost to follow-up (LTFU) could reverse the considerable gains achieved by ART programmes to date. 16 We sought to add to the data on changing outcomes associated with changing guidelines by comparing 12month LTFU and virologic suppression among HIVpositive ART-naïve patients initiating first-line ART after the implementation of the UTT policy change to patients initiating treatment under the previous ART guidelines within two large public-sector HIV clinics in Johannesburg, South Africa.
Methods

Study Design
We conducted a cohort analysis of prospectively collected data (Figure 1 ). Our study cohort consisted of HIVpositive adult patients who initiated standard first-line triple combination ART between 01 December 2014 and 31 May 2017. Standard first-line ART during the study period consisted of the fixed-dose combination (FDC), tenofovir (TDF) with lamivudine (3TC) or emtricitabine (FTC) and efavirenz (EFV) or a combination of other standard first-line drugs when a FDC could not be prescribed. All patients were followed-up from ART initiation until 12 months post-first-line therapy.
Study Population
The study population consisted of HIV-positive nonpregnant, ART-naïve adults (≥18 years at first-line ART initiation) without tuberculosis (TB), initiating a standard first-line ART regimen. As national test and treat algorithms differ according to pregnancy and TBinfection status, pregnant women and adults infected with TB were excluded from this analysis. [12] [13] [14] We compare two groups; 1) a pre-UTT (unexposed) group of all patients who initiated treatment prior to the implementation of UTT (01 December 2014-31 May 2015); and 2) an UTT (exposed) group of all patients who initiated treatment ≥3 months after the implementation of UTT (01 December 2016-31 May 2017) ( Figure 2 ) to allow the respective clinics to assimilate the change in guidelines ( Figure 1 ). We further stratify the UTT group into those who initiated treatment at a CD4 cell count ≤500 and >500 cells/mm 3 . As per national ART guidelines during respective enrolment periods, patients enrolled during the pre-UTT period initiated ART with CD4 cell counts ≤500 cells/mm 3 or with a WHO stage III/IV condition, 12, 13 while eligibility for ART initiation in the UTT period was based solely on patients positive HIV status. 14 Africa. 18 The clinics were established or expanded around 2004 as part of the public sector scale-up of ART in the country. The clinics receive technical support from Right to Care, a non-governmental organisation (NGO) funded by the United States Agency for International Development (USAID) from the President's Emergency Plan for AIDS Relief Programme (PEPFAR). While forming part of a larger clinical cohort consisting of six other clinics across two South African provinces, due to limited data availability as a result of many clinics in the cohort phasing out the longstanding existing patient management system, only the clinics listed here were considered for the analysis. 18, 19 HIV care and treatment within the clinics follow South African National ART Guidelines. [11] [12] [13] 20, 21 Clinical data were captured prospectively on-site and stored in an electronic patient management system, TherapyEdge-HIV™. 19 Additional clinical and laboratory data were obtained from electronic records held by the National Health Laboratory Services (NHLS), the primary provider of laboratory services for South Africa's public sector clinics.
Study Sites
Baseline Covariates
We defined baseline as the date of first-line ART initiation among ART-naïve patients. Baseline characteristics such as age, sex and initiating ART regimen were measured at ART initiation, while WHO stage, body mass index (BMI), and safety/work-up blood tests such as haemoglobin (Hb) and CD4 cell count were measured closest to date of ART initiation (90 days before to 7 days post-ART initiation).
Due to the setting of the clinic sites (high altitude), haemoglobin levels were first adjusted down by 0.65 g/ dL, and defined by sex for males as 1) no anaemia (Hb≥13 g/dL), 2) mild anaemia (10<Hb<13 g/dL), 3) moderate anaemia (8≤Hb≤10 g/dL) and 4) severe anaemia (Hb<8 g/dL); and for females as 1) no anaemia (Hb≥12 g/dL), 2) mild anaemia (10<Hb<12 g/dL), 3) moderate anaemia (8≤Hb≤10 g/dL) and 4) severe anaemia (Hb<8 g/dL). 22 
Outcomes
We compared the pre-UTT and UTT groups with respect to the following primary outcomes: 1) LTFU (defined as being >90 days late for the last scheduled visit with no subsequent visit) and 2) virologic suppression (defined as a viral load ≤400 copies/mL) at 12 months on ART (±3 months). Secondary outcomes included missing 12 months viral load measurement among those alive and in care on ART at 12 months (±3 months). When measuring LTFU, person-time accrued from ART initiation to the earliest of 1) LTFU; 2) death; 3) transfer out to another facility; 4) completed 12 months of follow-up. As noted, to account for some of the systematic differences between patients initiating ART across the two guideline groups, we also compare LTFU among a subpopulation of patients initiating treatment with a CD4 cell count ≤500 cells/mm 3 in both groups (pre-UTT vs UTT).
Statistical Analysis
Cox proportional hazards models were used to evaluate the relationship between pre-UTT vs UTT initiation and LTFU, while Kaplan-Meier survival analysis was used to determine the timing of LTFU by group. Poisson regression with robust standard errors 23 was used to estimate the association between pre-UTT vs UTT initiation for virologic suppression and missing viral load measurement at 12 months. All baseline characteristics know a priori to be confounders (age, sex, CD4 cell count) and/or those which resulted in a ≥10% change in the primary exposure effect were included in the respective adjusted models. Schoenfeld residuals were used to test the assumption of proportional hazards. All analyses presented correspond to a complete-case analysis.
Ethical Approval
All data were fully anonymised for analyses. Ethics approval for the retrospective data review was obtained from the Human Research Ethics Committee of the University of Witwatersrand (M140201) and the Boston University Institutional Review Board (H-29768).
Results
Demographic and Clinical Characteristics
We included 2410 patients in our analysis ( Figure 2 .5kg/m 2 was similar across the pre-UTT (11%) and UTT ≤500 cells/mm 3 (12%) groups, but less prevalent in the UTT >500 cells/mm 3 (3%) group.
By 12 months after starting ART, nearly two-thirds of all patients were still alive and in care (66%); this was lower among UTT initiates (≤500; 58% vs >500 cells/mm 3 ; 57%) when compared to pre-UTT initiates (75%) ( Table 2 ). Overall 12-months LTFU was higher among both groups of UTT initiates (≤500; 18% vs >500 cells/mm 3 ; 16%) when compared to pre-UTT initiates (10%). All-cause mortality was 3%, reported similarly across pre-UTT and UTT ≤500 cells/mm 3 (3%) groups but lower among the UTT >500 cells/mm 3 group (1%). Transfer-out was 12%, 22% and 27% across the pre-UTT and UTT (≤500 vs >500 cells/ mm 3 ) groups, respectively.
Slightly more than half (852/1599; 53%) of those alive and in care at 12 months on ART had a 12-months viral load assessment done. The majority of these patients achieved virologic suppression at this time (79 vs 89 vs 100% among pre-UTT, UTT ≤500 and UTT >500 cells/ mm 3 respectively).
LTFU by 12 Months on ART
In adjusted models, patients initiating ART under UTT were 50% more likely to be LTFU (adjusted Hazard Ratio (aHR): 1.51; 95% Confidence Interval (CI): 1.16-1.98) (Table 3) . Similarly, in this population, males (aHR: 1.48; 95% CI: 1.12-1.96), younger patients (18-29 vs 30-44 years; aHR: 1.49; 95% CI: 1.10-2.01), and those with moderate or severe anaemia at baseline (moderate vs none; aHR: 1.65; 95% CI: 1.10-2.50; severe vs none; aHR: 1.88; 95% CI: 1.09-3.25) were approximately 50% more likely to be lost from care by 12 months after the start of ART.
LTFU by 12 Months on ART -Among Patients with CD4 Cell Count ≤500 cells/ mm 3
When restricted to only patients initiating treatment with a CD4 cell count ≤500 cells/mm 3 , those initiating under UTT guidelines were 60% more likely to be LTFU by 12 months (aHR: 1.59; 95% CI: 1.21-2.10) ( Table 4 ). Males (aHR: 1.56; 95% CI: 1.16-2.08), younger patients (18-29 vs 30-44 years; aHR: 1.56; 95% CI: 1.14-2.14), and those with moderate anaemia at baseline (moderate vs none; aHR: 1.56; 95% CI: 1.04-2.36) were also more likely to be lost from care (56%).
Timing of LTFU by 12 Months on ART
The risk of LTFU was similar between UTT initiates (≤500 vs >500 cells/mm 3 ) in the first 6 months of treatment after which time the ≤500 cells/mm 3 group had a marginally higher risk of the outcome (Figure 3 ). By 12 months, approximately 80% and 82% of UTT initiates (≤500 vs >500 cells/mm 3 ) were still alive and in care compared to 90% of pre-UTT initiates. While common risk factors of LTFU include; dissatisfaction with health services, financial constraints, poor infrastructure surrounding health facilities and adverse effects of treatment, potential precursors to the outcome also include, improving health condition and higher initiating CD4 cell count. 16, [26] [27] [28] [29] [30] [31] The newly implemented treatment policy has resulted in patients initiating ART at increasingly better health status (moderately higher CD4 cell count in this study). These patients may not fully perceive the direct benefits of treatment, particularly in the context of travel time and transport costs to the clinic, long queues and waiting times. Additionally, first-line ART is prescribed with a strict adherence protocol. 32 The perceived non-benefit of treatment in addition to the health system barriers to easy access to HIV care may result in increased defaulter rates after ART initiation. Important to consider, patients initiating ART under UTT guidelines are eligible for treatment upon positive testing. Patients from this group who go on to initiate treatment, may not be subjected to the same pre-initiation protocols/procedures as those who initiate under pre-UTT guidelines who become eligible (CD4 ≤500 cells/mm 3 ) sometime after testing positive with a CD4 cell count >500 cells/mm 3 . The latter group, may then be more resilient once on treatment due to their sustained retention in pre-ART programmes.
Other risk factors of LTFU by 12 months on ART in this population (≥50% more likely to be LTFU) included; male gender, younger adults and anaemia. As commonly observed in resource-limited HIV treatment programmes, younger patients often face many barriers in accessing and maintaining HIV treatment. These barriers typically come in the form of negative attitudes and perceptions held by health-care workers such as counsellors and nurses, irregular routines while pursuing tertiary education and employment as well as higher risk-taking behaviour. 2, [33] [34] [35] HIV-positive patients with anaemia are often subject to other opportunistic infections, complications in treatment and disease progression; common risk factors to both mortality, disengagement with health services and potentially progression to higherlevel facilities/hospitalization. 36, 37 Patients initiating ART under UTT and those with higher CD4 cell counts (>200 cells/mm 3 ) were at least 15% more likely to achieve virologic suppression at 12 months on ART. While this may be a marginal increase, the higher suppression rates among those in better health at the start of treatment may speak to the rationale behind earlier ART initiation (at a higher CD4 cell count). Higher CD4 cell count at ART initiation has subsequently been established as a clinical characteristic generally leading to higher rates of virologic suppression on ART. 38 Higher rates of suppression among patients initiating treatment with higher CD4 cell counts may also account for the increase in missing viral load measurement among this group at 12 months on treatment. These patients, often in better health may not warrant closer viral load monitoring when compared to those with poorer virologic response early on in ART.
Limitations
Patients enrolled in the pre-UTT and UTT groups were enrolled in two mutually exclusive periods. This aspect of the study design was a function of the national treatment guideline changes between the study time periods and ensured two distinct treatment groups. While the nonoverlapping nature of our respective cohorts may allow direct comparisons of outcomes across respective periods, it may create confounding through changes or improvements in programmatic conditions between such periods. Programmatic changes (eg, tracing initiatives) could have potentially affected treatment outcomes investigated here, although we would expect such initiatives to improve over time, leading to lower rates of LTFU in the UTT period. A lack of pre-ART data among the pre-UTT group restricts our ability to directly assess the causal effect of UTT. Differences in the pre-ART initiation protocols across respective guidelines does not allow for the populations themselves to be directly comparable. However, in order to account for differences in eligibility between groups and its effect on pre-initiation protocols and outcomes, we compare a sub-population of the UTT group (CD4 cell count ≤500 cells/mm 3 ) to the pre-UTT group (CD4 cell count ≤500 cells/mm 3 ) with regard to LTFU. Initiating treatment under UTT guidelines, male gender, younger age and moderate anaemia were still identified as risk factors of LTFU by 12 months on treatment. In this study, we were only able to observe treatment outcomes within the first 12 months of ART. The period immediately following first-line ART initiation may be unique as patients adjust to lifelong therapy. Consequently, a larger cohort with longer follow-up time is needed to identify longer-term outcomes, which may differ from the initial effects of treatment initiation up to 12 months on treatment. Moreover, follow-up data are ascertained primarily from routinely collected clinical data, the limitations of which, including missingness is well-documented and should be acknowledged here. 39 Lastly, due to a lack of social and contextual data, our understanding of LTFU may be limited. Data relating to community and societal characteristics, income and social status, education level as well as stigma and barriers to treatment access are not routinely collected at the study sites. These factors are important to consider when developing a holistic understanding LTFU, 40 and results presented here should be interpreted alongside these limitations.
Conclusion
While the implementation of universal test and treat in South Africa may ensure greater access to treatment among all known HIV-positive patients and increase viral suppression among those alive and in care 12 months after starting ART, rates of LTFU under these newly rolled-out guidelines prove higher than those of previous periods (even when restricted to only patients initiating ART with a CD4 cell count ≤500 cells/mm 3 ). Patients initiating first-line therapy under the treat-all policy may often start treatment in better health, subsequently not perceiving a direct benefit to treatment. This coupled with the strict adherence protocol prescribed in first-line ART may deter patients from consistent engagement in HIV treatment programmes, while the need for sustained engagement with pre-ART programmes in order to initiate treatment, may lead to a more resilient pre-UTT population. 
